Drug Profile

Cetuximab biosimilar - R-Pharm

Alternative Names: Erbitux biosimilar - R-Pharm; RPH-002

Latest Information Update: 15 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator R-Pharm
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase III Head and neck cancer

Most Recent Events

08 Oct 2021 Phase III trial is still ongoing for Head and neck cancer and Colorectal cancer in Russia (R-Pharm pipeline, October 2021)
04 Sep 2017 Cetuximab biosimilar is still in clinical trials for Head and neck cancer (R-Pharm pipeline, August 2017)
15 May 2015 R-Pharm announces intention to submit MAA in Russia and Turkey in 2015

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com